Find Clinical Trials & Studies

Visit the Research & Education Institute

Lutetium (177Lu) rosopatamab tetraxetan w/ SOC in Prostate Cancer

I'm Interested!

Please call
1-800-641-2422

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment

Sex: Male
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Prostate

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Principal Investigator
Pedro Barata MD

Department/Division
Cancer (Genitourinary)

UH IRB: STUDY20240960
StudyID: TLIX1824
ClinicalTrials.gov: NCT06520345

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422